Evommune (EVMN) awards 100,000 stock options to its Chief Medical Officer

Rhea-AI Filing Summary

Evommune, Inc. reported an equity award to one of its senior leaders. On 12/08/2025, a reporting person who serves as both a director and Chief Medical Officer received an employee stock option to buy 100,000 shares of Evommune common stock at an exercise price of $18.44 per share. The option expires on 12/08/2035.

One fourth of the option shares will vest on December 8, 2026, and the remaining shares will vest in 36 equal monthly installments after that date, as long as the reporting person continues to provide service. After this grant, the reporting person beneficially owns 100,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bauer Eugene

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1841 PAGE MILL ROAD, SUITE 100

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$18.44	12/08/2025		A		100,000		(1)	12/08/2035	Common Stock	100,000	$0.00	100,000	D

Explanation of Responses:

1. One fourth (1/4) of the shares subject to the option award shall vest on December 8, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	12/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Evommune (EVMN) disclose in this Form 4?

Evommune disclosed that a reporting person who is both a director and Chief Medical Officer received an employee stock option on 12/08/2025.

How many shares are covered by the new Evommune (EVMN) stock option grant?

The employee stock option covers 100,000 shares of Evommune common stock underlying the derivative security.

What is the exercise price of the Evommune (EVMN) stock options granted on 12/08/2025?

The exercise price of the stock option is $18.44 per share of Evommune common stock.

What is the vesting schedule for the Evommune (EVMN) stock option award?

One fourth of the option shares vest on December 8, 2026, and the remaining shares vest in 36 equal monthly installments thereafter, subject to continuous service.

When do the newly granted Evommune (EVMN) options expire?

The employee stock option award has an expiration date of 12/08/2035.

How many derivative securities does the reporting person own after this Evommune (EVMN) transaction?

Following this transaction, the reporting person beneficially owns 100,000 derivative securities directly.